Amiodarone is an effective antiarrhythmic medication frequently used in practice for both
Key
Amiodarone pharmacokinetic profile(9,10,15,24)
0000000000000487 The authors present a case of a 69-year-old
5 mg/L appears to be the most herapeutic drug concentrations of amiodarone and its active metabolite
Clinical follow-up is essential for optimal use of amiodarone
Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem
2 – 0
Amiodarone is an iodinated benzofuran derivative that was synthesized and tested as an antianginal agent in the 1960s but was later discovered to have antiarrhythmic properties
Narrow therapeutic index (NTI) drugs are defined as those drugs where small differences in dose or blood concentration may lead to dose and blood concentration dependent, serious therapeutic failures or adverse drug reactions
Therapeutic drug monitoring for amiodarone and coadministered medications is highly recommended
Amiodarone is a class III antiarrhythmic drug used to prevent supraventricular and ventricular tachyarrhythmias
Z79
Further study is warranted to demonstrate whether these services impact the overall quality of care provided to patients receiving amiodarone, which may justify To (a) assess rates of laboratory monitoring of liver, thyroid, and pulmonary function and adverse events in a pharmacist-managed amiodarone monitoring program compared with usual care in an integrated health care system and (b) estimate return on investment (ROI) from this intervention
1365-2125
Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and Amiodarone (AMI) is the most effective antiarrhythmic medication available today for the treatment of both atrial and ventricular arrhythmias (Kumar and Zimetbaum, 2013)
TDM can be useful in the case of amiodarone to monitor compliance and toxicity but is generally of little value for sotalol
However, this drug is also widely used off-label to treat supraventricular tachyarrhythmias, such as atrial